This funding opportunity supports basic research aimed at understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic opioids such as fentanyl, carfentanil, and nitazenes, including their combinations like fentanyl and xylazine. It also supports studies on persistent or delayed pathophysiological effects following such exposures. Clinical trials are not allowed under this initiative.
Eligible applicants include a wide range of organizations such as tribal governments, nonprofits, for-profit organizations, educational institutions, government entities, and community-based organizations. Non-domestic entities and foreign components of U.S. organizations are not eligible.
